Epigenetics Market (By Product: Kits, Reagents Enzymes, Instruments And Consumables, Bioinformatic Tools; By Technology: DNA Methylation, Histone Modification, Other Technologies; By Application: Oncology, Non - oncology; By End-User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Contract Research Organizations) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
The global epigenetics market size was surpassed at USD 2.14 billion in 2023 and it is expected to hit around USD 7.02 billion by 2033 and poised to grow at a CAGR of 12.56% from 2024 to 2033.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. epigenetics market size was valued at USD 600 million in 2023 and is expected to reach USD 2,080 million by 2033, growing at a CAGR of 13.23% from 2024 to 2033.
North America region generated more than 40.13% of revenue share in 2023 and is predicted to lead the global epigenetics demand over the projected period due to the rising percentage of tumor patients in the area, as well as the innovative economic state of nations such as the United States and Canada, where the population's income capability is comparatively higher, and they are able to afford the cost of cancer therapies.
The governments' excellent healthcare reimbursement laws are anticipated to entice people to enroll in cancer treatment, which will help regional growth. Increased investment in epigenetics investigation in the United States may also support this sector. Chroma Medicine, Inc. (Chroma) was founded in November 2021 with a capital of USD 125 million to address a wide range of diseases and emerge as the technique of choice for the regulation of gene expression. Due to the aforementioned factors, the market in this region should grow.
Asia-Pacific is expected to expand significantly, owing to rising medical tourism in regions such as India and China, because of the presence of relatively lower therapies. The increasing strategic partnerships between international agencies and private players to grow their consumer records may also be related to regional growth.
Epigenetics is the investigation of changes in heritable phenotypes that occur without any modifications to DNA Sequencing. The expanding application of epigenetics is expected to propel the epigenetics industry forward. Furthermore, rising cardiovascular disease, cancer, and genetic disorder incidences, combined with enhanced R&D activities in DND sequencing, encourage the market.
Several cancers, cardiovascular diseases, respiratory infections, reproductive issues, cognitive dysfunction, and autoimmune disorder difficulties may be linked to epigenetic mechanisms, either directly or indirectly. Agents that contribute to such diseases as pesticides, heavy metals, hormones, cigarette smoke, radiation, environmental variables, viruses, or essential nutrition are also increasing, strengthening market growth.
Furthermore, the increasing aging population in different nations is likely to assist the emerging market. On the other hand, the high upfront and ongoing costs of the equipment prove to be a significant hindrance to market growth.
Report Coverage | Details |
Growth Rate from 2024 to 2033 | CAGR of 12.56% |
Market Size in 2023 | USD 2.14 Billion |
Market Size by 2033 | USD 7.02 Billion |
Largest Market | North America |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Segments Covered | By Product, By Technology, By Application, and By End-User |
Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Drivers
Rising prevalence of cancer
The growing number of epigenetic applications in cancer treatment as well as other disorders is predicted to propel the global epigenetics industry growth. Numerous research institutes are thoroughly investigating epigenetics with the goal of developing necessary vaccines and drugs for abnormalities that do not currently have any effective therapies assigned to them because it has been demonstrated to be highly effective in treating specific types of cancer.
Organizations such as the National Cancer Institute, Human Epigenome Consortium, and National Institute of Health have advocated for increased spending in epigenetics not only for research but also for commercialization, which is anticipated to aid global expansion in the following years.
A rise in the aging population is expected to boost market growth.
According to WHO, the worldwide population of people aged 65 and up is estimated to grow from 1 billion in the year 2019 to approximately 2.1 billion in 2050, with emerging nations accounting for a major rise. Aging is regarded as the leading cause of neurological diseases and cardiovascular diseases, so it is expected to aggravate these diseases.
Furthermore, aging weakens the body's immunity system and increases the possibility of acquiring infectious diseases. Moreover, the rising elderly population in Asian countries such as Japan, India, and China which have significant potential, is anticipated to propel market expansion over the predicted period.
Restraints
Rising R&D costs for improving novel products, as well as a stringent approval procedure, are impeding the market growth.
Before being commercialized, the appropriate regulatory authorities must approve novel epigenetic drugs. This framework for drug approval is time-consuming as well as strict. There are currently no ethical policies in emerging nations such as China and India, where the diagnostic industry has significant growth potential because of the large patient pool.
However, a shortage of skilled labor and insufficient coverage for health insurance in remote locations are two significant impediments to the expansion of this market.
Opportunities
Use in personalized medicines.
Patients are given genomic or personalized medicines after gathering genetic data as well as associated information such as levels of RNA, proteins, and various metabolites, which are crucial elements in medical decision-making for personalized medicine. For precise disease management and prediction management, genomic strategies like transcriptomics, identifying DNA sequence variations, metabolomics, and proteomics are useful.
These strategies are effective tools for bridging the gap between epigenetics and personalized medicine. Furthermore, information from a specific genome sequence, as well as the associated biomarkers, are required for personalized and genomic therapies to be recognized.
Impact of COVID-19:
COVID-19 had an encouraging effect on the epigenetics industry. Although there is no FDA-approved medicine or vaccine to cure coronavirus infection, a few therapeutic combinations have now been evaluated to help patients survive the virus. Moreover, antiviral drugs like remdesivir, rapamycin, and ribavirin, as well as epigenetic drugs like BRD4 inhibitors, DNMT1 inhibitors, and HDAC inhibitors, have been found to reduce virus activity.
Researchers have begun to understand how epigenetics may restrict viral multiplication to formulate vaccines and therapies that specifically target a virus's mutating mechanisms. Hence, the epigenetics industry is anticipated to gain from a rise in the percentage of epigenetic research and a greater understanding of epigenetic drugs used in the therapy of coronavirus infection.
Reagents led the industry in terms of products in 2023. The epigenetic reagents are DNA modifiers and histones. Antibodies, histones, PCR reagents, electrophoresis reagents, primers, buffers, and nucleic acid reagents are common reagents of epigenetics. PyroMark Q24, an advanced reagent, uses innovative pyrosequencing chemistry to provide sequence-based quantification and detection than previously available. Epigenetic aspects such as DNA methylation, non-coding RNA, and chromatin structure influence gene regulation. The widespread use of reagents has a significant impact on the market for analytical tools and life sciences.
During the projected period, the kits sector is anticipated to grow the largest CAGR. Many biotechnology companies produce kits that are ready to use for the identification of epigenetic alterations. DNA methylation analysis and identification of histone alterations by specific enzymes are available on the market.
Epigenetic diagnostic kits diagnose disorders caused by epigenetic changes in the initial stages of therapy and evaluate the effectiveness of therapeutics. These kits rely on the principle of immunoprecipitation through the use of monoclonal antibodies.
In 2023, DNA methylation held the largest share of the epigenetics industry. The covalent introduction of a methyl group to the cytosine ring in DNA results in transcription inhibition. Methylation-sensitive PCR refers to sensitive bisulfite modification followed by PCR. Technological advancements are making it possible to assess DNA methylation in a genome.
The histone acetylation sector is predicted to expand the fastest during the forecast years to improve efficacy as a result of new mechanisms. It's the enzymatic addition to a lysine molecule. Histone acetylation regulates cellular processes like chromatin dynamics and transcription, gene silencing, cell cycle progression, differentiation, DNA replication, apoptosis, neuronal repression, DNA repair, and nuclear import. Histone Acetyl Transferases (HATs) are enzymes engaged in histone acetylation, and histone deacetylases are enzymes involved in histone deacetylation.
In 2023, oncology accounted for roughly 70.0% of the global market revenue. The rising prevalence of cancer globally and the increasing number of cancer-related deaths are driving the segment's growth. Furthermore, the launch of new products as well as the possible commercialization of products in the pipeline in the coming years, are expected to drive segment growth.
Non-oncology is expected to grow at a faster rate during the projected period. The segment's expansion can be attributed to stringent R&D programs launched by private organizations and biopharmaceutical industries to identify epigenetic markers associated with these diseases.
Epigenetic changes are at the root of a variety of non-oncological illnesses, including metabolic disorders, neurodegenerative disorders, and infectious diseases. In order to find biomarkers for pharmaceutical research, private institutions, and biopharmaceutical companies conduct extensive research.
Pharmaceutical and biotechnological companies led the global market in 2023, and this trend is expected to continue during the projection period due to enhanced R&D initiatives in genetics as well as towards the advancement of disease-specific therapies and analysis of resistance of drugs in microbes and molecular research of cancer as well as other disorders. Startups and SMEs are making investments in the epigenetics industry to create novel treatment methods.
In November 2021, Chroma Medicine announced plans to develop an epigenetic with the ability to alter how genes make proteins. This startup has received USD 125 million in funding from Newpath Partners, Atlas Venture, and other investors. The company intends to develop pharmaceuticals using gene-editing techniques. The company is planning to use gene-editing methods to develop treatments that can alter the epigenome, which is a game changer in the treatment of hereditary disorders.
On the other hand, academic and research institutes are anticipated to grow at the fastest CAGR from 2024 to 2033. The enhanced use of epigenetics products in government research institutions and university laboratories is the primary source of revenue for the academic and research institutes sector.
Segments Covered in the Report
By Product
By Technology
By Application
By End-User
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Epigenetics Market
5.1. COVID-19 Landscape: Epigenetics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Epigenetics Market, By Product
8.1. Epigenetics Market, by Product, 2024-2033
8.1.1. Kits
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Reagents
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Enzymes
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Instruments and Consumables
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Bioinformatic Tools
8.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Epigenetics Market, By Technology
9.1. Epigenetics Market, by Technology, 2024-2033
9.1.1. DNA Methylation
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Histone Modification
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Other Technologies
9.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Epigenetics Market, By Application
10.1. Epigenetics Market, by Application, 2024-2033
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Non - oncology
10.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Epigenetics Market, By End-User
11.1. Epigenetics Market, by End-User, 2024-2033
11.1.1. Academic and Research Institutes
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Pharmaceutical and Biotechnology Companies
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Contract Research Organizations
11.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 12. Global Epigenetics Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2021-2033)
12.1.2. Market Revenue and Forecast, by Technology (2021-2033)
12.1.3. Market Revenue and Forecast, by Application (2021-2033)
12.1.4. Market Revenue and Forecast, by End-User (2021-2033)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.1.5.2. Market Revenue and Forecast, by Technology (2021-2033)
12.1.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.1.5.4. Market Revenue and Forecast, by End-User (2021-2033)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.1.6.2. Market Revenue and Forecast, by Technology (2021-2033)
12.1.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.1.6.4. Market Revenue and Forecast, by End-User (2021-2033)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.2. Market Revenue and Forecast, by Technology (2021-2033)
12.2.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.4. Market Revenue and Forecast, by End-User (2021-2033)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.5.2. Market Revenue and Forecast, by Technology (2021-2033)
12.2.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.5.4. Market Revenue and Forecast, by End-User (2021-2033)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.6.2. Market Revenue and Forecast, by Technology (2021-2033)
12.2.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.6.4. Market Revenue and Forecast, by End-User (2021-2033)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.7.2. Market Revenue and Forecast, by Technology (2021-2033)
12.2.7.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.7.4. Market Revenue and Forecast, by End-User (2021-2033)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.8.2. Market Revenue and Forecast, by Technology (2021-2033)
12.2.8.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.8.4. Market Revenue and Forecast, by End-User (2021-2033)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.2. Market Revenue and Forecast, by Technology (2021-2033)
12.3.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.4. Market Revenue and Forecast, by End-User (2021-2033)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.5.2. Market Revenue and Forecast, by Technology (2021-2033)
12.3.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.5.4. Market Revenue and Forecast, by End-User (2021-2033)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.6.2. Market Revenue and Forecast, by Technology (2021-2033)
12.3.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.6.4. Market Revenue and Forecast, by End-User (2021-2033)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.7.2. Market Revenue and Forecast, by Technology (2021-2033)
12.3.7.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.7.4. Market Revenue and Forecast, by End-User (2021-2033)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.8.2. Market Revenue and Forecast, by Technology (2021-2033)
12.3.8.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.8.4. Market Revenue and Forecast, by End-User (2021-2033)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.2. Market Revenue and Forecast, by Technology (2021-2033)
12.4.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.4. Market Revenue and Forecast, by End-User (2021-2033)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.5.2. Market Revenue and Forecast, by Technology (2021-2033)
12.4.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.5.4. Market Revenue and Forecast, by End-User (2021-2033)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.6.2. Market Revenue and Forecast, by Technology (2021-2033)
12.4.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.6.4. Market Revenue and Forecast, by End-User (2021-2033)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.7.2. Market Revenue and Forecast, by Technology (2021-2033)
12.4.7.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.7.4. Market Revenue and Forecast, by End-User (2021-2033)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.8.2. Market Revenue and Forecast, by Technology (2021-2033)
12.4.8.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.8.4. Market Revenue and Forecast, by End-User (2021-2033)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.5.2. Market Revenue and Forecast, by Technology (2021-2033)
12.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.5.4. Market Revenue and Forecast, by End-User (2021-2033)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.5.5.2. Market Revenue and Forecast, by Technology (2021-2033)
12.5.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.5.5.4. Market Revenue and Forecast, by End-User (2021-2033)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.5.6.2. Market Revenue and Forecast, by Technology (2021-2033)
12.5.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.5.6.4. Market Revenue and Forecast, by End-User (2021-2033)
Chapter 13. Company Profiles
13.1. Bio-Rad
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Illumina
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. QIAGEN
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Thermo Fisher
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Active Motif
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Diagenode
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Agilent
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Merck Millipore
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Abcam
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. New England Biolabs
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client